Physician profile
Carter E Gibson
NPI 1437181138
$2,559.30
in general payments reported to CMS, 2019-2025
21 companies · $197 in 2025
The $197 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $599 · 2021: $243 · 2022: $132 · 2023: $687 · 2024: $470 · 2025: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,353.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $425.97 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $297.91 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $242.13 | 2019-2021 | |
| Glaxosmithkline, LLC. | $165.42 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $158.16 | 2023-2024 | |
| Abbvie INC. | $150.06 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.50 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $142.47 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $140.66 | 2019-2024 | Breztri, Farxiga |
| Exact Sciences Corporation | $138.53 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.22 | 2023-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $98.54 | 2019-2023 | Belsomra, Steglatro |
| Astellas Pharma US INC | $93.95 | 2019-2025 | Veozah |
| Amgen INC. | $67.28 | 2019-2024 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $52.17 | 2019-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $34.80 | 2024 | Opsumit, Uptravi |
| Abbott Laboratories | $23.48 | 2020 | |
| Dexcom, INC. | $23.08 | 2023 | Dexcom G6 Transmitter |
| Hikma Pharmaceuticals USA | $21.48 | 2020 | |
| Amneal Pharmaceuticals LLC | $16.82 | 2024 | Rytary |
| Teva Pharmaceuticals USA, INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carter Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.